bioMerieux (OTCMKTS:BMXMF) Sets New 52-Week High - Should You Buy?

Key Points

• bioMerieux shares recently hit a new 52-week high, trading at $149.38 after closing at $135.05.
• The Royal Bank of Canada downgraded bioMerieux from a "moderate buy" to a "hold" rating on May 7th.
• The company has a healthy financial status, reflected in a debt-to-equity ratio of 0.08 and a current ratio of 2.20.
• bioMerieux specializes in in vitro diagnostic solutions for infectious diseases across multiple regions, including the Americas and Europe.

Shares of bioMerieux (OTCMKTS:BMXMF - Get Free Report) reached a new 52-week high during trading on Friday . The stock traded as high as $149.38 and last traded at $149.38, with a volume of 11 shares trading hands. The stock had previously closed at $135.05.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada cut shares of bioMerieux from a "moderate buy" rating to a "hold" rating in a report on Wednesday, May 7th.

bioMerieux Stock Performance

The business has a fifty day moving average of $138.93 and a 200 day moving average of $128.87. The company has a quick ratio of 1.29, a current ratio of 2.20 and a debt-to-equity ratio of 0.08.

About bioMerieux

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.